Published in Cancers (Basel) on May 26, 2010
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci (1991) 5.88
Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 5.70
Neural stem cells and the origin of gliomas. N Engl J Med (2005) 5.43
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol (2003) 3.60
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev (2008) 3.51
Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest (2009) 3.23
Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med (2000) 2.85
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res (2006) 2.62
Pharmacological actions of cannabinoids. Handb Exp Pharmacol (2005) 2.56
Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology (2004) 2.18
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res (2009) 2.11
Molecularly targeted therapy for malignant glioma. Cancer (2007) 1.96
The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell (2006) 1.85
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci (2006) 1.80
Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience (2005) 1.76
The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs (2005) 1.75
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther (2006) 1.61
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res (2001) 1.49
Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat (2000) 1.48
Cannabinoids for cancer treatment: progress and promise. Cancer Res (2008) 1.46
Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem (2000) 1.43
Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci (1998) 1.39
Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett (1998) 1.37
Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology (2001) 1.35
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther (2008) 1.25
A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer (2006) 1.24
The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J (2000) 1.19
Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol (2006) 1.18
The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol (2000) 1.17
Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) (2006) 1.16
Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther (2007) 1.14
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther (2003) 1.12
Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. Ann N Y Acad Sci (2008) 1.11
Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal (2005) 1.07
5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem (2007) 1.05
The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci (2006) 1.04
Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther (2001) 1.02
Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther (2010) 1.00
Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem (2007) 0.99
Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets (2009) 0.99
Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem J (2002) 0.99
Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett (2000) 0.94
Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol Sci (2001) 0.92
Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism. Mol Cancer Res (2009) 0.90
A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int Immunopharmacol (2008) 0.90
Treatment options for recurrent glioblastoma: pitfalls and future trends. Expert Rev Anticancer Ther (2009) 0.87
Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J Neurochem (2006) 0.87
Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J Neuropathol Exp Neurol (2004) 0.86
Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull (2009) 0.86
Delta9-tetrahydrocannabinol increases C6 glioma cell death produced by oxidative stress. Neuroscience (2005) 0.85
Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res (2006) 0.84
Novel immunotherapeutic approaches to glioma. Curr Opin Mol Ther (2006) 0.82
Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurol Sci (2008) 0.82
Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol (2001) 0.80
Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem (2008) 0.78
Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation. Neuropharmacology (2001) 0.78
Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. J Neurooncol (2005) 0.76
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry (2011) 2.25
Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. Clin Immunol (2006) 1.69
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med (Berl) (2007) 1.65
Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther (2005) 1.56
Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology (2008) 1.44
Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus (2009) 1.40
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol (2002) 1.40
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J (2006) 1.36
A molecular basis of analgesic tolerance to cannabinoids. J Neurosci (2007) 1.28
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol (2005) 1.23
Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav (2005) 1.22
A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J (2004) 1.21
Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol (2011) 1.21
Endocannabinoids link feeding state and auditory perception-related gene expression. J Neurosci (2004) 1.18
Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol (2004) 1.16
Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology (2005) 1.12
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther (2003) 1.12
Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) (2007) 1.12
Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry (2007) 1.09
Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol (2009) 1.07
Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology (2005) 1.06
Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci (2007) 1.03
Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. J Neurochem (2005) 1.02
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol (2010) 1.01
Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend (2002) 1.00
Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology (2007) 1.00
Cannabidiol as potential anticancer drug. Br J Clin Pharmacol (2013) 1.00
Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem Pharmacol (2005) 0.99
Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade. Mol Neurobiol (2006) 0.97
Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology (2005) 0.97
Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology (2003) 0.96
Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem (2005) 0.96
SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance. Nat Neurosci (2012) 0.96
Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol Cell Neurosci (2004) 0.95
Comparative analysis of molecular strategies attenuating positional effects in lentiviral vectors carrying multiple genes. J Virol Methods (2006) 0.94
Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) (2005) 0.93
Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. Br J Pharmacol (2004) 0.93
Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. Eur J Neurosci (2004) 0.92
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis (2005) 0.92
Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. Front Behav Neurosci (2011) 0.91
ERK-dependent modulation of cerebellar synaptic plasticity after chronic Delta9-tetrahydrocannabinol exposure. J Neurosci (2006) 0.89
AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br J Pharmacol (2012) 0.87
Cannabimimetic activity, binding, and degradation of stearoylethanolamide within the mouse central nervous system. Mol Cell Neurosci (2002) 0.87
Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol (2008) 0.87
Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. Neuropharmacology (2008) 0.87
Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Int J Neuropsychopharmacol (2010) 0.87
Long-term consequences of URB597 administration during adolescence on cannabinoid CB1 receptor binding in brain areas. Brain Res (2008) 0.85
Intrauterine position has long-term influence on brain mu-opioid receptor density and behaviour in mice. Psychoneuroendocrinology (2003) 0.83
Transcriptomic and proteomic analyses of mouse cerebellum reveals alterations in RasGRF1 expression following in vivo chronic treatment with delta 9-tetrahydrocannabinol. J Mol Neurosci (2008) 0.82
Chronic treatment with polychlorinated biphenyls (PCB) during pregnancy and lactation in the rat: Part 1: Effects on somatic growth, growth hormone-axis activity and bone mass in the offspring. Toxicol Appl Pharmacol (2009) 0.82
Cannabinoids and opioids share cAMP pathway in rat splenocytes. J Neuroimmunol (2003) 0.82
Expression and function of the endocannabinoid system in glial cells. Curr Pharm Des (2008) 0.80
Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. Life Sci (2004) 0.79
Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. Int J Neuropsychopharmacol (2010) 0.79
Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS One (2013) 0.79
Sex-dependent changes in brain CB1R expression and functionality and immune CB2R expression as a consequence of maternal deprivation and adolescent cocaine exposure. Pharmacol Res (2013) 0.78
Chronic treatment with the endocannabinoid anandamide increases cytochrome P450 metabolizing system in the rat. Eur J Pharmacol (2002) 0.78
Binding of δ9-tetrahydrocannabinol and diazepam to human serum albumin. IUBMB Life (2011) 0.78
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects. Br J Pharmacol (2015) 0.76
The endocannabinoid system and schizophrenia: integration of evidence. Curr Pharm Des (2012) 0.76
[Adolescent cannabis consumption and schizophrenia: epidemiological and experimental evidences]. Adicciones (2010) 0.75
Estrogenic effect of procymidone through activation of MAPK in MCF-7 breast carcinoma cell line. Life Sci (2005) 0.75